SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin jumps on receiving European Marketing Authorization for Nepexto, Biosimilar Etanercept

05 Jun 2020 Evaluate
Lupin is currently trading at Rs. 915.30, up by 7.60 points or 0.84% from its previous closing of Rs. 907.70 on the BSE.

The scrip opened at Rs. 917.50 and has touched a high and low of Rs. 923.55 and Rs. 908.05 respectively. So far 60560 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 923.55 on 05-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 923.55 and Rs. 845.60 respectively. The current market cap of the company is Rs. 41337.20 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.

Lupin and Mylan N.V. have received European Marketing Authorization for Nepexto, a biosimilar to Enbrel (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and nonradiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

The regulatory approval follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) in March this year, which was based on a biosimilarity assessment including preclinical and clinical studies demonstrating bioequivalence to Enbrel. In addition, a phase 3 clinical study in patients with moderatetosevere active rheumatoid arthritis confirmed equivalence of Nepexto to Enbrel in terms of efficacy, safety and immunogenicity.

Lupin is an innovationled transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×